Immunopharmacology: Immunomodulation and immunotherapy

JAMA

Volumn 278, Issue 22, 1997, Pages 2008-2017

  Ballow, Mark ^a   Nelson, Robert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; CYTOKINE; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; IMMUNOGLOBULIN; INTEGRIN; INTERLEUKIN 12; INTERLEUKIN 2; METHOTREXATE; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; GENE THERAPY; GENETIC DISORDER; HOST RESISTANCE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LONG TERM CARE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; WHOLE BODY RADIATION;

EID: 0031469099     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.22.2008     Document Type: Review

References (90)

1. NIH Consensus Conference. The utility of therapeutic plasmapheresis for neurological disorders. JAMA. 1986;256:1333-1777.
2. Shumak KH, Rock GA. Therapeutic plasma exchange. N Engl J Med. 1984;310:762-771.
3. Brostoff J, Scadding GK, Male DM, Roitt IM. Clinical Immunology. New York, NY: Gower Medical Publishing; 1991:27.1-27.10.
4. Levitt SH, McHugh RB. Early breast cancer and postoperative radiation. Lancet. 1975;2:1258-1259.
5. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Paternack BS. Treatment of Crohn's disease with 6-mercaptopurine. N Engl J Med. 1980; 302:981-987.
6. Sullivan KM, Mori M, Sanders J. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant. 1992;10:127-134.
7. Zaharko DS, Fung W-P, Yang F-H. Relative biochemical aspects of low and high doses of methotrexate in mice. Cancer Res. 1977;37:1602-1607.
8. Roenigk HH, Auerbach R, Maibach HI. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol. 1988;19:145-156.
9. Mullarkey M. Immunosupppressive therapy for asthma. Allergy Proc. 1995;16:81-84.
10. Stewart GE II, Diaz JD, Lockey RF, Seleznick MJ, Trudeau WL, Ledford DK. Comparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid-dependent asthma. J Allergy Clin Immunol. 1994;94:482-489.
11. Giannini EH, Brewer EJ, Kuzmina N. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. N Engl J Med. 1992;326:1043-1049.
12. Gilbert SC, Klintmalm G, Menter A. Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis: a word of caution in light of the expanding use of this 'steroid sparing' agent. Arch Intern Med. 1990;150:889-891.
13. Calabresi P, Chabner BA. Antineoplastic agents. In: Gilman AG, Pall RN, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. New York, NY: McGraw Hill; 1993.
14. Boumpas DT, Austin HA, Fessler BJ. Systemic lupus erythematosus: emerging concepts, I: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med. 1995;122:940-950.
15. Fauci AS, Haynes BF, Katz P. Wegeners granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98:76-85.
16. Mattila PS. The actions of cyclosporin A and FK 506 on T-lymphocyte activation. Biochem Soc Trans. 1996;24:45-49.
17. Ellis CN, Fradin MS, Messana JM. Cyclosporine for plague-type psoriasis: results of a multidose, double-blind trial. N Engl J Med. 1991;324:277-284.
18. Masuda K, Nakajima A, Urayama A, Kogure M. Double-masked trial of cyclosporin versus colchi cine and long-term open study of cyclosporin in Behcet's disease. Lancet. 1989;1:1093-1096.
19. Bougneres PF, Landais P, Boisson C. Limited duration of remission of insulin dependency in children with recent overt type 1 diabetes treated with low-dose cyclosporin. Diabetes. 1990;39:1264-1272.
20. Muraoka K, Fujimoto K, Sun X, et al. Immuno-suppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kB. J Clin Invest. 1996;97:2433-2439.
21. Sehgal S, Camardo J, Scarola J, Maida B. Rapamycin (sirolimus,rapamune). Curr Opin Nephrol Hypertens. 1995;4:482-487.
22. Brazelton T, Morris R. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol. 1996;8:710-720.
23. Yocum D. Cyclosporine,FK506, rapamycin, and other immunomodulators. Rheumatol Dis Clin North Am. 1996;22:133-154.
24. Morris R. New immunosuppressive drugs: mycophenolate mofetil. New Dev Transplant Med. 1995;2:10-12.
25. Siemasko K, Chong A, Williams J, Bremer E, Finnegan A. Regulation of B-cell function by the immunosuppressive agent leflunomide. Transplantation. 1996;61:635-642.
26. Vallera DA. Immunotoxins: will their clinical promise be fulfilled? Blood. 1994;83:309-317.
27. Vitetta ES, Thorpe PE, Uhr JW. Immunotoxins: magic bullets or misguided missiles? Immunol Today. 1993;14:252-259.
28. Mayforth RD, Quintans J. Designer and catalytic antibodies. N Engl J Med. 1990;323:173-178.
29. Chatenoud L, Bach J-F. Monoclonal antibodies to CDS as immunosuppressants. Semin Immunol. 1990;2:437-447.
30. Horneff G, Emmrich F, Burmester GR. Advances in immunotherapy in rheumatoid arthritis: clinical and immunological findings following treatment with anti-CD4 antibodies. Br J Rheumatol. 1993;32:39-47.
31. Herzog C, Walker C, Miller W. Anti-CD4 antibody treatment of patients with rheumatoid arthritis, I: effect on clinical course and circulating T cells. J Autoimmun. 1989;2:627-642.
32. Moreland LW, Bucy RP, Tilden A. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum. 1993;36:307-318.
33. Choy EH, Chikanza IC, Kingsley GH, Corrigall V, Panayi GS. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol. 1992; 36:291-298.
34. van der Lubbe PA, Dijkmans BA, Markusse HM, Nassander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum. 1995;38:1097-1106.
35. Cush JJ, A F Kavanaugh M. Biologic interventions in rheumatoid arthritis. Rheum Dis Clin North Am. 1995;21:797-816.
36. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthr Rheum. 1994;37:992-999.
37. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science. 1990;247:456-459.
38. Lefkovits J, Plow EG, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
39. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
40. Elliott MJ, Maini RN, Feldmann M. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994; 344:1105-1110.
41. Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 1995;34:334-342.
42. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA. 1993;269: 1829-1835.
43. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind multicenter clinical trial. JAMA. 1995;273:934-941.
44. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 1991;5:2567-2574.
45. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990;113:619-627.
46. Arend WP. Interleukin-1 receptor antagonist: a new member of the interleukin-1 family. J Clin Invest. 1991;54:1445-1451.
47. Fisher CJ, Dhainaut J-FA, Opal SM. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized double-blind, placebo-controlled trial. JAMA. 1994;271:1836-1843.
48. van der Meer JWM, Barza M, Wolff SM, Dinarello CA. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci USA. 1988; 85:1620-1623.
49. Wallach D, Holtmann H, Engelmann H, Nophar Y. Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol. 1988; 140:2994-2999.
50. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med. 1996;334: 1697-702.
51. Beato M. Gene regulation by steroid hormones. Cell. 1989;56:335-344.
52. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of 1 kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286.
53. Flower RJ. Glucocorticoids and the inhibition of phospholipase A2. In: Schleimer RP, ed. Anti-inflammatory Steroid Action: Basic and Clinical Aspects. San Diego, Calif: Academic Press; 1989.
54. Sorensen RU, Polmar SH. Efficacy and safety of high dose immune globulin therapy for antibody deficiency syndromes. Am J Med. 1984;76:83-90.
55. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia: defection of IgE antibodies to IgA. N Engl J Med. 1986;314:560-564.
56. Kressebuch H, Schaad UB, Hirt A. Cerebrospinal fluid inflammation induced by intravenous immunoglobulins. Pediatr Infect Dis J. 1992;11:894-895.
57. Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United States, October 1993-June 1994. JAMA. 1994;272: 424-425. Originally published in: MMWR Morbid Mortal Wkly Rep. 1994;43:505-509.
58. Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United States, October 1993-June 1994. JAMA. 1994;272: 424-425. Originally published in: MMWR Morbid Mortal Wkly Rep. 1994;43:505-509.
59. Bjorkander J, Cunningham-Rundles C, Lundin P. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med. 1988;84:107-111.
60. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol. 1997;100: 151-157.
61. Imbach P, Wagner H, Berchtold W. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet. 1985;2:464-468.
62. Furusho K, Kamiya T, Nakano H. High-dose intravenous gamma-globulin for Kawasaki disease. Lancet. 1984;2:1055-1058.
63. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000.
64. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA, and the University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA. 1995;273:1865-1870.
65. Balkwill FR. Interferons. Lancet. 1989;1:1060-1063.
66. Kimchi A. Autocrine Interferon and the suppression of the c-myc nuclear oncogene. Interferon. 1987;8:86-110.
67. Dorr RT. Interferon-α in malignant and viral diseases. Drugs. 1993;45:177-211.
68. Davis G, Balart L, Schiff E. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med. 1989;321:1501-1506.
69. Perrillo R, Schiff E, Davis G. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 1990;323:295-301.
70. Sibley W, Ebers G, Panitch H. Interferon beta-Ib is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology. 1993;43:655-661.
71. International Chronic Granulomatous Disease Cooperative Study Group: a controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991;324: 509-516.
72. Rosenberg S, Lotze M, Muul L. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485-1492.
73. Lotze M, Matory Y, Rayner A. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986;58:1764-1772.
74. Rosenberg S, Lotze M, Yang J. Experience with the use of high dose interleukin-2 based therapies in the treatment of 652 patients with cancer. Ann Surg. 1989;210:474-484.
75. Rosenberg S. Adoptive cellular therapy: clinical applications. In: DeVita V, ed. Biologic Therapy of Cancer. Philadelphia, Pa: Lippincott; 1991.
76. Caligiuri M, Murray C, Soiffer R. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol. 1991;9: 2110-2119.
77. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med. 1996;335:1350-1356.
78. Cunningham-Rundles C, Kazbay K, Zhou Z, Mayer L. Immunologic effects of low-dose polyethylene glycol-conjugated recombinant human interleukin-2 in common variable immunodeficiency. J Int Cytol Res. 1995;15:269-276.
79. Chehimi J, Trinchieri G. Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol 1994;14:149-161.
80. Grant SM, Heel RC. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): a review of its pharmacological properties and prospective role in the management of myelosuppression. Drugs. 1992;43:516-560.
81. Nemanaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773-1778.
82. Antman KS, Griffin JD, Elias A. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988;319:593-598.
83. Greenberg PL, Negrin R, Nagler A. The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes. Cancer Surv. 1990;9:199-212.
84. Weite K, Zeidler C, Reiter A, et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood. 1990;75:1056-1063.
85. Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. N Engl J Med. 1995;333: 431-440.
86. Hirschhorn R. Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency. Pediatr Res. 1993;33:35-41.
87. Hershfield MS. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunapathol. 1995;76:228-232.
88. Kohn DB, Weinberg KI, Nolta JA. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med. 1995;1:1017-1023.
89. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270:475-480.
90. Candotti F, Johnston JA, Puck JM, Sugamura K, O'Shea JJ, Blaese RM. Retroviral-mediated gene correction for X-linked severe combined immunodeficiency. Blood. 1996;87:3097-3102.